Patents by Inventor Leonid Beigelman

Leonid Beigelman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • OLIGONUCLEOTIDE CONSTRUCTS AND USES THEREOF
    Publication number: 20190160173
    Abstract: Oligodeoxynucleotide-based immunostimulatory Toll-Like Receptor 9 (TLR9) agonists are described. Also described are compositions comprising the TLR9 agonists, methods of making the TLR9 agonists, and methods of using the TLR9 agonists to treat immune diseases, disorders or conditions, such as viral infections or cancer.
    Type: Application
    Filed: November 2, 2018
    Publication date: May 30, 2019
    Inventors: Sergei Gryaznov, Leonid Beigelman, Theodore Yun
  • Aza-pyridone compounds and uses thereof
    Patent number: 10251882
    Abstract: Disclosed herein are aza-pyridone compounds, pharmaceutical compositions that include one or more aza-pyridone compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an orthomyxovirus infection, with an aza-pyridone compounds. Examples of an orthomyxovirus viral infection include an influenza infection.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: April 9, 2019
    Assignee: Alios BioPharma, Inc.
    Inventors: Robert Than Hendricks, Leonid Beigelman, David Bernard Smith, Antitsa Dimitrova Stoycheva
  • SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF
    Publication number: 20190085011
    Abstract: Disclosed herein are nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a HCV infection with one or more nucleotide analogs.
    Type: Application
    Filed: November 28, 2018
    Publication date: March 21, 2019
    Inventors: Leonid Beigelman, Guangyi Wang, David Bernard Smith
  • RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA)
    Publication number: 20190062746
    Abstract: The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against target nucleic acid sequences. The small nucleic acid molecules are useful in the treatment of any disease or condition that responds to modulation of gene expression or activity in a cell, tissue, or organism.
    Type: Application
    Filed: November 7, 2018
    Publication date: February 28, 2019
    Inventors: Leonid Beigelman, James McSwiggen, Chandra Vargeese
  • ACYCLIC ANTIVIRALS
    Publication number: 20190055273
    Abstract: Disclosed herein are nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a HBV and/or HDV and/or HIV infection with one or more nucleotide analogs
    Type: Application
    Filed: March 9, 2017
    Publication date: February 21, 2019
    Inventors: Leonid BEIGELMAN, Guangyi WANG, Minghong ZHONG
  • SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF
    Publication number: 20190054108
    Abstract: Disclosed herein are nucleosides, nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a Filoviridae virus infection with one or more nucleosides and/or nucleotide analogs.
    Type: Application
    Filed: August 20, 2018
    Publication date: February 21, 2019
    Inventors: Lawrence M. Blatt, Leonid Beigelman, Natalia Dyatkina, Julian Alexander Symons, David Bernard Smith
  • Aza-pyridone compounds and uses thereof
    Patent number: 10208045
    Abstract: Disclosed herein are aza-pyridone compounds, pharmaceutical compositions that include one or more aza-pyridone compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an orthomyxovirus infection, with an aza-pyridone compound. Examples of an orthomyxovirus viral infection include an influenza infection.
    Type: Grant
    Filed: March 9, 2016
    Date of Patent: February 19, 2019
    Assignee: Alios BioPharma, Inc.
    Inventors: Robert Than Hendricks, Leonid Beigelman, David Bernard Smith, Antitsa Dimitrova Stoycheva
  • SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF
    Publication number: 20190031703
    Abstract: Disclosed herein are nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a HCV infection with one or more nucleotide analogs.
    Type: Application
    Filed: October 16, 2018
    Publication date: January 31, 2019
    Inventors: Leonid Beigelman, Guangyi Wang, David Bernard Smith
  • Method of preparing AZA-pyridone compounds
    Patent number: 10183945
    Abstract: Disclosed herein are methods for obtaining aza-pyridone compounds, which can be useful for ameliorating and/or treating a disease and/or a condition, including an orthomyxovirus infection.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: January 22, 2019
    Assignee: ALIOS BIOPHARMA, INC.
    Inventors: Michael Hunter Welch, Leonid Beigelman, Robert Than Hendricks, Andras Horvath, Gareth Brown, Prasad Ganji, Stefan Mix
  • RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA)
    Publication number: 20190010497
    Abstract: The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against target nucleic acid sequences. The small nucleic acid molecules are useful in the treatment of any disease or condition that responds to modulation of gene expression or activity in a cell, tissue, or organism.
    Type: Application
    Filed: September 19, 2018
    Publication date: January 10, 2019
    Inventors: Leonid Beigelman, James McSwiggen, Chandra Vargeese
  • Double stranded oligonucleotide compounds comprising positional modifications
    Patent number: 10144928
    Abstract: Disclosed herein are double stranded RNA molecules which have been modified to exhibit one of the following, increased activity, enhanced nuclease stability, reduced off target activity and or reduced immunogenicity, to pharmaceutical compositions comprising such compounds and to methods of use. Further disclosed is a method for the synthesis of threose nucleic acid phosphoramidites and methods of use thereof.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: December 4, 2018
    Assignee: Quark Pharmaceuticals, Inc.
    Inventors: Sharon Avkin-Nachum, Elena Feinstein, Leonid Beigelman
  • Substituted nucleosides, nucleotides and analogs thereof
    Patent number: 10144755
    Abstract: Disclosed herein are nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a HCV infection with one or more nucleotide analogs.
    Type: Grant
    Filed: September 2, 2016
    Date of Patent: December 4, 2018
    Assignee: Alios BioPharma, Inc.
    Inventors: Leonid Beigelman, Guangyi Wang, David Bernard Smith
  • Substituted nucleosides, nucleotides and analogs thereof
    Patent number: 10112966
    Abstract: Disclosed herein are nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a HCV infection with one or more nucleotide analogs.
    Type: Grant
    Filed: September 2, 2016
    Date of Patent: October 30, 2018
    Assignee: Alios BioPharma, Inc.
    Inventors: Leonid Beigelman, Guangyi Wang, David Bernard Smith
  • RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA)
    Publication number: 20180245083
    Abstract: The present invention concerns methods and reagents useful modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against target nucleic acid sequences. The small nucleic acid molecules are useful in the treatment of any disease or condition that responds to modulation of gene expression or activity in a cell, issue, or organism.
    Type: Application
    Filed: May 11, 2018
    Publication date: August 30, 2018
    Inventors: Leonid Beigelman, James McSwiggen, Chandra Vargeese
  • Substituted nucleosides, nucleotides and analogs thereof
    Patent number: 10052342
    Abstract: Disclosed herein are nucleosides, nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a Filoviridae virus infection with one or more nucleosides and/or nucleotide analogs.
    Type: Grant
    Filed: February 8, 2017
    Date of Patent: August 21, 2018
    Assignee: Alios BioPharma, Inc.
    Inventors: Lawrence M. Blatt, Leonid Beigelman, Natalia Dyatkina, Julian Alexander Symons, David Bernard Smith
  • SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF
    Publication number: 20180194793
    Abstract: Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection, with a nucleoside, a nucleotide and an analog thereof.
    Type: Application
    Filed: February 13, 2018
    Publication date: July 12, 2018
    Inventors: Natalia Dyatkina, Guangyi Wang, Leonid Beigelman, Vivek Kumar Rajwanshi
  • METHODS OF PREPARING SUBSTITUTED NUCLEOSIDE ANALOGS
    Publication number: 20180186825
    Abstract: Disclosed herein are methods of preparing a nucleoside analog, which are useful in treating diseases and/or conditions such as viral infections, and intermediates thereof.
    Type: Application
    Filed: February 26, 2018
    Publication date: July 5, 2018
    Inventors: Vladimir Serebryany, Jyanwei Liu, Leonid Beigelman
  • RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
    Patent number: 10000754
    Abstract: The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against target nucleic acid sequences. The small nucleic acid molecules are useful in the treatment of any disease or condition that responds to modulation of gene expression or activity in a cell, tissue, or organism.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: June 19, 2018
    Assignee: SIRNA THERAPEUTICS, INC.
    Inventors: Leonid Beigelman, James McSwiggen, Chandra Vargeese
  • CYCLIC DINUCLEOTIDES AS STING AGONISTS
    Publication number: 20180162899
    Abstract: Disclosed are compounds, compositions and methods for treating viral infections, diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I) as follows: wherein R1A, R1B, R1c, B1, R2A, and R2B are defined herein.
    Type: Application
    Filed: November 22, 2017
    Publication date: June 14, 2018
    Inventors: Gilles Bignan, Peter Connolly, James Patrick Edwards, Stuart Emanuel, Sylvie Laquerre, Tianbao Lu, Mark Richter, Leonid Beigelman, Santhosh Kumar Thatikonda, Guangyi Wang, Minghong Zhong
  • Compounds and methods for treating inflammatory and fibrotic disorders
    Patent number: RE47142
    Abstract: Disclosed are compounds and methods for treating inflammatory and fibrotic disorders, including methods of modulating a stress activated protein kinase (SAPK) system with an active compound, wherein the active compound exhibits low potency for inhibition of the p38 MAPK; and wherein the contacting is conducted at a SAPK-modulating concentration that is at a low percentage inhibitory concentration for inhibition of the p38 MAPK by the compound. Also disclosed are derivatives and analogs of pirfenidone, useful for modulating a stress activated protein kinase (SAPK) system. Mederski et al., Tetrahedron (1999), 55(44), 12757-12770.* Azuma et al., “A placebo control and double blind phase II clinical study of pirfenidone in patients with idiopathic pulmonary fibrosis in Japan”, Am J Respir Crit Care Med., 165:A729 (2002). Badger, et al.
    Type: Grant
    Filed: November 6, 2014
    Date of Patent: November 27, 2018
    Assignee: InterMune, Inc.
    Inventors: Karl Kossen, Scott D. Seiwert, Vladimir Serebryany, Donald Ruhrmund, Leonid Beigelman, Luca Francesco Mario Raveglia, Stefania Vallese, Ivana Bianchi, Tao Hu